JP6944936B2 - 血液癌を処置するためのセルデュラチニブ - Google Patents

血液癌を処置するためのセルデュラチニブ Download PDF

Info

Publication number
JP6944936B2
JP6944936B2 JP2018528591A JP2018528591A JP6944936B2 JP 6944936 B2 JP6944936 B2 JP 6944936B2 JP 2018528591 A JP2018528591 A JP 2018528591A JP 2018528591 A JP2018528591 A JP 2018528591A JP 6944936 B2 JP6944936 B2 JP 6944936B2
Authority
JP
Japan
Prior art keywords
cerduratinib
pharmaceutically acceptable
acceptable salt
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018528591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535996A (ja
JP2018535996A5 (https=
Inventor
グレゴリー コフィー，
グレゴリー コフィー，
ジャジャ フェン，
ジャジャ フェン，
アンドリュー スティール，
アンドリュー スティール，
Original Assignee
ポートラ ファーマシューティカルズ， インコーポレイテッド
ポートラ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， インコーポレイテッド, ポートラ ファーマシューティカルズ， インコーポレイテッド filed Critical ポートラ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2018535996A publication Critical patent/JP2018535996A/ja
Publication of JP2018535996A5 publication Critical patent/JP2018535996A5/ja
Application granted granted Critical
Publication of JP6944936B2 publication Critical patent/JP6944936B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018528591A 2015-12-04 2016-12-02 血液癌を処置するためのセルデュラチニブ Expired - Fee Related JP6944936B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562263582P 2015-12-04 2015-12-04
US62/263,582 2015-12-04
US201662342755P 2016-05-27 2016-05-27
US201662342727P 2016-05-27 2016-05-27
US62/342,727 2016-05-27
US62/342,755 2016-05-27
US201662371145P 2016-08-04 2016-08-04
US62/371,145 2016-08-04
PCT/US2016/064824 WO2017096303A2 (en) 2015-12-04 2016-12-02 Cerdulatinib for treating hematological cancers

Publications (3)

Publication Number Publication Date
JP2018535996A JP2018535996A (ja) 2018-12-06
JP2018535996A5 JP2018535996A5 (https=) 2020-01-09
JP6944936B2 true JP6944936B2 (ja) 2021-10-06

Family

ID=57614468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528591A Expired - Fee Related JP6944936B2 (ja) 2015-12-04 2016-12-02 血液癌を処置するためのセルデュラチニブ

Country Status (8)

Country Link
US (2) US10736895B2 (https=)
EP (1) EP3383396B1 (https=)
JP (1) JP6944936B2 (https=)
CN (1) CN108367006B (https=)
AU (1) AU2016363005A1 (https=)
CA (1) CA2950640A1 (https=)
ES (1) ES2959692T3 (https=)
WO (1) WO2017096303A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
SG11202005781WA (en) * 2018-01-09 2020-07-29 Dermavant Sciences GmbH Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib
EP3787628A1 (en) * 2018-05-04 2021-03-10 Portola Pharmaceuticals, Inc. Methods for treating lymphoma
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
SG11202108770TA (en) * 2019-02-15 2021-09-29 Janssen Biotech Inc Combination therapy for treatment of b-cell malignancies
US20230181581A1 (en) * 2020-05-26 2023-06-15 Alexion Pharmaceuticals, Inc. Circulating b cell subpopulations in indolent b cell lymphoma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA024109B1 (ru) 2008-04-16 2016-08-31 Портола Фармасьютиклз, Инк. Ингибиторы протеинкиназ
AR076550A1 (es) 2009-05-06 2011-06-22 Portola Pharm Inc Inhibidores de la janus tirosina kinasa (jak)
NZ595708A (en) 2009-05-26 2014-03-28 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20110130415A1 (en) 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
US9357229B2 (en) 2010-07-28 2016-05-31 Qualcomm Incorporated Coding motion vectors in video coding
WO2012045020A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016196385A1 (en) 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
JP6833816B2 (ja) 2015-08-12 2021-02-24 ポートラ ファーマシューティカルズ， インコーポレイテッド 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
EP3788035B1 (en) 2018-05-04 2024-08-07 Alexion Pharmaceuticals, Inc. Solid forms of cerdulatinib

Also Published As

Publication number Publication date
US20180353506A1 (en) 2018-12-13
ES2959692T3 (es) 2024-02-27
US20210000827A1 (en) 2021-01-07
JP2018535996A (ja) 2018-12-06
EP3383396A2 (en) 2018-10-10
US10736895B2 (en) 2020-08-11
EP3383396B1 (en) 2023-07-12
WO2017096303A2 (en) 2017-06-08
CN108367006A (zh) 2018-08-03
AU2016363005A1 (en) 2018-07-05
CA2950640A1 (en) 2017-06-04
CN108367006B (zh) 2021-12-31
US11446300B2 (en) 2022-09-20
WO2017096303A3 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
JP6944936B2 (ja) 血液癌を処置するためのセルデュラチニブ
US12350269B2 (en) Cerdulatinib for the treatment of b-cell malignancies
US9259399B2 (en) Targeting CDK4 and CDK6 in cancer therapy
JP2020045350A (ja) 癌を治療するための併用療法
TW201325593A (zh) 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
CN114246864B (zh) Csf1r激酶抑制剂及其用途
US20200289520A1 (en) Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
KR20170005125A (ko) 클래스 ⅲ 수용체 티로신 키나제 억제제 및 알킬화 히스톤-디아세틸라제 억제제 융합 분자 edo-s101을 포함하는 약학적 조합물 및 암 치료에 사용되는 이의 용도
US11872220B2 (en) Methods and compositions for treating B-cell malignancies
HK1262118A1 (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1262118B (en) Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
HK1253804B (en) Cerdulatinib for the treatment of b-cell malignancies
HK1253804A1 (en) Cerdulatinib for the treatment of b-cell malignancies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210913

R150 Certificate of patent or registration of utility model

Ref document number: 6944936

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees